Paper Details

  1. Home
  2. Paper Details

Daunorubicin during delayed intensification decreases the incidence of infectious complications - a randomized comparison in trial CoALL 08-09.

Author: BeronGerhard, BorkhardtArndt, ChristiansenHolger, EscherichGabriele, FaberJörg, FeuchtingerTobias, HorstmannMartin A, ImschweilerThomas, JorchNorbert, PekrunArnulf, SchmidIrene, SchrammFranziska, ZimmermannMartin

Clinical Trial, Phase IIA Phase II trial is a trial that further evaluates the efficacy and safety of a new drug or treatment, whose safety has been confirmed to some extent in a Phase I trial, in a small number of patients.
Clinical Trial, Phase IIIA Phase III trial is a trial that further rigorously verifies the efficacy and safety of a new drug or treatment, whose efficacy and safety have been confirmed in a Phase II trial, in a large number of patients, and evaluates whether it is superior to existing treatments.
Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.

Overview

This study compared the effects of doxorubicin (DOX) and daunorubicin (DNR), two anthracycline drugs used to treat leukemia. The researchers found that DNR was associated with a lower rate of infectious complications than DOX, with no difference in efficacy or survival.
Paper Details　
Original Abstract of the Article :
Anthracyclines are integral components of antileukemic treatment. Apart from cardiotoxicity, myelosuppression and infectious complications have been described for doxorubicin (DOX) and daunorubicin (DNR) as predominant side effects, but little is known about their differential toxicities. To address...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1080/10428194.2018.1473575

データ提供：米国国立医学図書館（NLM）

Daunorubicin vs. Doxorubicin: A Choice in the Desert of Leukemia Treatment

Treating leukemia is a relentless battle, like navigating a vast desert with shifting sands. Anthracyclines, powerful drugs like desert oases, play a crucial role in this fight, but they can also cause side effects, like a treacherous sandstorm.

This study, like a careful scout, compared the effects of two anthracyclines, daunorubicin and doxorubicin, on children with leukemia. Their findings revealed that daunorubicin was associated with a lower rate of infectious complications, offering a potentially safer path through the desert of treatment.

Finding the Safest Route in the Desert

This research provides valuable insights for clinicians, suggesting that daunorubicin might be a better choice for certain patients, particularly those at higher risk of infections. This could lead to better outcomes and a smoother journey through treatment.

Protecting Children in the Desert of Leukemia

This study is a beacon of hope for families facing the challenge of childhood leukemia. It underscores the importance of careful consideration of treatment options and individualized care to ensure the safest and most effective path to recovery.

Dr.Camel's Conclusion

The fight against leukemia is a long and challenging journey through a desert of uncertainty. This study offers a valuable map, highlighting the potential benefits of daunorubicin and emphasizing the need for personalized care to ensure the safest and most effective treatment for children facing this disease.

Date :
  1. Date Completed 2019-12-31
  2. Date Revised 2019-12-31
Further Info :

Pubmed ID

29966458

DOI: Digital Object Identifier

10.1080/10428194.2018.1473575

Related Literature

Article Analysis
・Side Effects of daunorubicin
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.